Greenstaff Life Sciences has launched a referral programme designed to connect exceptional talent in the life sciences sector with the right career opportunities. When someone you refer secures a role through us and completes one month of continuous employment, you will receive a ¥20,000 gift card as a token of appreciation. Programme details are available […]
AstraZeneca has signed a licensing agreement with Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical, for ex-China rights to TQC3721, a chronic obstructive pulmonary disease candidate. The deal is drawing attention as another sign that China-origin clinical assets are becoming part of global pharma pipeline strategy beyond oncology, metabolic, and kidney disease. Deal Highlights $200M […]
Novartis has announced that it will acquire U.K.-based biotech company Myricx Bio. The transaction is drawing attention as another signal that, in ADCs, differentiation is increasingly moving beyond tumor target selection and toward payload innovation. Deal Highlights $1.1B upfront; total potential value of up to $1.5B Next-generation ADC platform using N-myristoyltransferase inhibitor (NMTi) payload technology […]
Ipsen has announced that it will acquire U.S.-based Kartos Therapeutics. The transaction includes an upfront payment of $450 million and up to $1.3 billion in development, regulatory, and sales milestones, bringing the total potential value to up to $1.75 billion. Deal Highlights $450M upfront; total potential value of up to $1.75B Navtemadlin: late-stage MDM2 inhibitor […]
AbbVie has announced that it will acquire Apogee Therapeutics, a biotech company focused on immunology and inflammatory diseases, in a cash transaction valued at approximately $10.9 billion. Through the acquisition, AbbVie will gain Apogee’s long-acting antibody pipeline, led by zumilokibart. Deal Highlights Transaction value of approximately $10.9 billion Purchase price of $135.11 per share Lead […]
uniQure has outlined plans to move forward with a Biologics License Application for AMT-130, its investigational gene therapy for Huntington’s disease, under the FDA’s accelerated approval pathway. According to reports, the FDA has agreed that three-year Phase 1/2 data from AMT-130 can serve as the primary basis for the application. uniQure plans to submit the […]
GSK has announced that it will acquire oncology biotech Nuvalent in a $10.6 billion cash transaction. Nuvalent is developing targeted therapies for non-small cell lung cancer, including its lead candidates zidesamtinib and neladalkib, which are currently under FDA review. Deal Overview $10.6 billion cash transaction Purchase price of $124 per share Lead candidates include zidesamtinib […]
Pfizer has entered into a global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The agreement covers 12 early-stage oncology programs, including antibody-drug conjugates and multispecific antibodies. Innovent will receive $650 million upfront, with the remaining value tied to development, regulatory, and commercial milestones. Collaboration Overview 12 early-stage oncology programs 8 Innovent-originated candidates […]
Eli Lilly and Company has announced acquisitions of three vaccine developers – Curevo, LimmaTech Biologics, and Vaccine Company – in deals valued at up to approximately $3.8 billion combined. The move signals Lilly’s renewed focus on infectious disease prevention and vaccine innovation. Acquisition Overview Curevo | up to $1.5B Developing a next-generation shingles vaccine candidate, […]
Two new treatments across very different therapeutic areas and modalities have received regulatory approvals in the U.S. and UK. AstraZeneca’s Baxfendy (baxdrostat) has been approved by the U.S. FDA as a new treatment option for adults with uncontrolled hypertension, in combination with other antihypertensive medicines. Meanwhile, Krystal Biotech’s VYJUVEK (beremagene geperpavec-svdt) has been approved by […]
Bristol Myers Squibb and Hengrui Pharma have announced a global strategic collaboration and licensing agreement worth up to $15.2 billion. The collaboration covers 13 early-stage programmes across oncology, hematology, and immunology. Rather than a single asset licensing deal, this partnership combines multiple candidates and newly discovered programmes within a broader co-development framework. Partnership highlights 13 […]